Equity Profile

ARGX

argenx SE

Health CareBiotechnology$55.4B

Jul23Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

argenx SE (ARGX) is a biotechnology company focused on developing innovative therapies for patients with severe autoimmune diseases. With a market cap of $48 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs through its advanced drug development programs.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and successfully commercialize its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.11%

Avg Stock Reaction

+0.79%

Last Quarter Recap

In Q1-2026, argenx reported an EPS of $5.52, surpassing estimates by 6.94%. Despite the positive earnings surprise, the stock experienced a slight decline of 2.51% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about argenx's upcoming earnings report, given its history of beating EPS estimates. However, there is uncertainty regarding revenue figures and future guidance.

Bull Case

If argenx continues its trend of exceeding EPS expectations, it could signal strong operational performance and market confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong track record of EPS surprises, this figure will be critical in determining market reaction and investor sentiment.

What guidance will management provide for future revenue growth?

Investors will closely scrutinize any forward-looking statements, as guidance can significantly impact stock performance and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate argenx's ability to leverage its recent drug developments, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 15.57% move, indicating significant uncertainty that may not be justified by historical performance.

The company's consistent EPS beats suggest a stronger operational foundation than analysts may be acknowledging.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The debate centers around whether argenx can maintain its strong earnings momentum in a competitive biotechnology landscape.

Bull Confirmed If

An EPS of $6.00 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $5.00 would support the bear case, suggesting potential operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±15.57%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move of about 15.57%, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±14.7% while ARGX has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.0%

Calls (2K)P/C Ratio: 0.03Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If argenx beats expectations and raises guidance, history suggests the stock could rise by about 0.79% on the following day.

In-Line / Cautious

If the results are in line with expectations but management is cautious, the stock may experience muted movement as investors digest the commentary.

Miss

If the company misses EPS estimates, history suggests a potential decline of around 2.51% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or clinical trial results.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management and operational efficiency.
4Insights into partnerships or collaborations that could drive growth.
5Future guidance on revenue expectations and strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Domino's Pizza, Inc.

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and successfully commercialize its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.11%

Avg Stock Reaction

+0.79%

Last Quarter Recap

In Q1-2026, argenx reported an EPS of $5.52, surpassing estimates by 6.94%. Despite the positive earnings surprise, the stock experienced a slight decline of 2.51% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If argenx continues its trend of exceeding EPS expectations, it could signal strong operational performance and market confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong track record of EPS surprises, this figure will be critical in determining market reaction and investor sentiment.

What guidance will management provide for future revenue growth?

Investors will closely scrutinize any forward-looking statements, as guidance can significantly impact stock performance and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate argenx's ability to leverage its recent drug developments, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 15.57% move, indicating significant uncertainty that may not be justified by historical performance.

The company's consistent EPS beats suggest a stronger operational foundation than analysts may be acknowledging.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The debate centers around whether argenx can maintain its strong earnings momentum in a competitive biotechnology landscape.

Bull Confirmed If

An EPS of $6.00 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $5.00 would support the bear case, suggesting potential operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±15.57%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move of about 15.57%, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±14.7% while ARGX has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.0%

Calls (2K)P/C Ratio: 0.03Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If argenx beats expectations and raises guidance, history suggests the stock could rise by about 0.79% on the following day.

In-Line / Cautious

If the results are in line with expectations but management is cautious, the stock may experience muted movement as investors digest the commentary.

Miss

If the company misses EPS estimates, history suggests a potential decline of around 2.51% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or clinical trial results.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management and operational efficiency.
4Insights into partnerships or collaborations that could drive growth.
5Future guidance on revenue expectations and strategic initiatives.